^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H4 inhibitor

    Related drugs:
    2ms
    ABL103-1001: A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, ABL Bio, Inc. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    ABL103
    3ms
    ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=65, Recruiting, ABL Bio, Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • ABL103
    6ms
    GCT1047-01: GEN1047 for Solid Tumors - First in Human (FIH) Trial (clinicaltrials.gov)
    P1/2, N=179, Active, not recruiting, Genmab | Trial completion date: Mar 2027 --> Dec 2025 | Trial primary completion date: Jan 2027 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    GEN1047
    7ms
    A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint Therapies. (PubMed, Mol Cancer Ther)
    Additionally, combining PF-07260437 with standard of care (palbociclib plus fulvestrant) and a checkpoint inhibitor (anti-PD-1) showed combinatorial benefits in an immune competent in vivo model. Finally, the manageable toxicity profile of PF-07260437 was highlighted in an exploratory toxicology study in cynomolgus monkeys. These data support the clinical testing of PF-07260437 for treating B7-H4 expressing solid tumors, including breast cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    Ibrance (palbociclib) • fulvestrant • PF-07260437
    10ms
    ABL103-1001: A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, ABL Bio, Inc. | Trial primary completion date: Nov 2024 --> Jun 2025
    Trial primary completion date
    |
    ABL103
    1year
    FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=95, Terminated, Five Prime Therapeutics, Inc. | Phase classification: P1a/1b --> P1 | Completed --> Terminated; The Sponsor terminated the study for reasons unrelated to safety.
    Phase classification • Trial termination • Metastases
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    VTCN1 underexpression
    |
    Keytruda (pembrolizumab) • alsevalimab (FPA150)
    1year
    GCT1047-01: GEN1047 for Solid Tumors - First in Human (FIH) Trial (clinicaltrials.gov)
    P1/2, N=179, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=400 --> 179
    Enrollment closed • Enrollment change
    |
    GEN1047
    1year
    Phase I of XKH002 Injection in Patients (clinicaltrials.gov)
    P1, N=110, Recruiting, Zhejiang Kanova Biopharmaceutical Co., LTD | Not yet recruiting --> Recruiting
    Enrollment open
    1year
    CLN-418-001: CLN-418 Study on Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=48, Completed, Cullinan Therapeutics Inc. | Recruiting --> Completed | N=108 --> 48 | Trial completion date: Jun 2024 --> Sep 2024
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    HBM7008
    over1year
    GCT1047-01: GEN1047 for Solid Tumors - First in Human (FIH) Trial (clinicaltrials.gov)
    P1/2, N=400, Recruiting, Genmab | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    GEN1047
    over1year
    A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=40, Terminated, NextCure, Inc. | Trial completion date: Oct 2024 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Jan 2024; Due to the limited activity in Phase 1, NextCure decided to discontinue development of the anti-B7-H4 antibody monotherapy trial (NC762-01) to move forward with a prioritized B7-H4 ADC program.
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    NC762
    almost2years
    GCT1047-01: GEN1047 for Solid Tumors - First in Human (FIH) Trial (clinicaltrials.gov)
    P1/2, N=500, Recruiting, Genmab | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    GEN1047